Regular treatment with formoterol for chronic asthma: serious adverse events
about
Addition of anti-leukotriene agents to inhaled corticosteroids in children with persistent asthmaAddition to inhaled corticosteroids of long-acting beta 2-agonists versus anti-leukotrienes for chronic asthmaRegular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse eventsCombination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and childrenAddition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma.Combination fluticasone and salmeterol versus fixed dose combination budesonide and formoterol for chronic asthma in adults and childrenAddition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and childrenFormoterol versus short-acting beta-agonists as relief medication for adults and children with asthmaAddition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and childrenRegular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse eventsCombination formoterol and inhaled steroid versus beta2-agonist as relief medication for chronic asthma in adults and childrenCombination formoterol and budesonide as maintenance and reliever therapy versus inhaled steroid maintenance for chronic asthma in adults and childrenManagement of acute asthma in adults in the emergency department: nonventilatory managementThe Saudi initiative for asthma - 2012 update: Guidelines for the diagnosis and management of asthma in adults and childrenRosiglitazone reverses salbutamol-induced β(2) -adrenoceptor tolerance in airway smooth muscle
P2860
Q24197585-51DA51BF-9D3F-4803-8DE5-5499DB47AA4DQ24200999-F86C7CD4-DBEA-414A-B08A-4A775ADAB453Q24201048-4020D4A4-A886-4973-86B9-153A93A0676FQ24201774-EF9BBA98-C67B-4DE5-A59E-40F5C4DC7785Q24234499-409E2C02-A09B-4619-AEBC-4AF78241D4D7Q24234581-EFCC1687-6180-460B-9A29-EF762966C3D7Q24235303-02F1C900-98EF-49D1-8D3B-CDA30A724FA9Q24235496-06B47BAC-213B-45B5-A0D8-3C000B50BA9BQ24240464-21B3D08A-0762-4DDE-929F-F53EDDE09747Q24240832-A34B3D53-1030-46F3-A28B-DA12282E5739Q24241025-FCF70FB7-CCF3-4784-B028-FA9686CB70EBQ24241556-64F59802-D0B1-4BFA-B77C-EB3B5AA023FFQ28393362-690AA04A-294F-4429-9EB3-4C4B7BB7F3F4Q36422663-3632C7A3-39A6-4C3A-8AC6-C44444AB31D2Q41828663-B4A09060-7091-4FC8-ACF1-8200D1846D08
P2860
Regular treatment with formoterol for chronic asthma: serious adverse events
description
2008 nî lūn-bûn
@nan
2008 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Regular treatment with formoterol for chronic asthma: serious adverse events
@en
Regular treatment with formoterol for chronic asthma: serious adverse events
@en-gb
Regular treatment with formoterol for chronic asthma: serious adverse events
@nl
type
label
Regular treatment with formoterol for chronic asthma: serious adverse events
@en
Regular treatment with formoterol for chronic asthma: serious adverse events
@en-gb
Regular treatment with formoterol for chronic asthma: serious adverse events
@nl
prefLabel
Regular treatment with formoterol for chronic asthma: serious adverse events
@en
Regular treatment with formoterol for chronic asthma: serious adverse events
@en-gb
Regular treatment with formoterol for chronic asthma: serious adverse events
@nl
P2093
P2860
P1476
Regular treatment with formoterol for chronic asthma: serious adverse events
@en
P2093
Christopher J Cates
Matthew J Cates
Toby J Lasserson
P2860
P356
10.1002/14651858.CD006923.PUB2
P577
2008-10-08T00:00:00Z